SBP-101 not checked

Panbela Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“small molecule polyamine metabolic inhibitor for subcutaneous injection”In the company’s words, NCT05254171 on ClinicalTrials.gov
Tested for
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Main trialPhase 2/3
“The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.”In the company’s words, NCT05254171 on ClinicalTrials.gov
Other names
ivospemin · diethyl dihydroxyhomospermine

Other drugs for Pancreatic Cancer Metastatic

All 203 drugs for Pancreatic Cancer Metastatic

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 29 Aug 2026 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Phase 1Completed 28 Feb 2022 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SBP-101

Following is part of Solo: you see every change to SBP-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in